Impressed with a 50% success rate?

Witnessing blinding acute angle attacks motivated Dr Judy Ku’s passion for primary angle closure disease. She explores how a 50% success rate sounds impressive, but its real-world outcomes are less, especially when factoring in the economic costs of large population screening and proactive treatment. So, while laser peripheral iridotomy is effective in reducing the risk progression to primary angle closure and acute angle closure attacks – what are the caveats? Listen in to find out.

View Article here

Superiority complex? It is complex

Associate Professor Susan Carden examines the RAINBOW study, which compared treatment of ROP with ranibizumab versus laser therapy. Noting the extension trial may uncover more, there might be a superior treatment method. Listen in to find out more.

View article here 

Susan Carden is an Associate Professor in the Department of Pediatrics, University of Melbourne.  She is a Consultant Ophthalmologist RCH and is head of the Education Vision Assessment Unit, RVEEH. She currently chairs the Victorian Branch, RANZCO.  Her areas of 

expertise includes retinopathy of prematurity, Low Vision, paediatric ophthalmology and general ophthalmology and international development.

For Fuchs’s sake, taking out the sting

Hyperosmolar Eye Drops for Diurnal Corneal Edema in Fuchs’ Endothelial Dystrophy

Professor Stephanie Watson talks taking the sting out of Hyperosmolar Eye Drops for Diurnal Corneal Edema in Fuchs’ Endothelial Dystrophy. Do the clinical outcomes support their use, and how robust was this Double-Masked, Randomized Controlled Trial?

View article here

Stephanie Watson is the Head of the Corneal Research Group at the Save Sight Institute at the University of Sydney. She is the co-Deputy Director of Industry, Innovation and Commercialisation at Sydney Nano, the Head of the Corneal Unit at Sydney Eye Hospital and Chair of Australian Vision Research (formerly Ophthalmic Research Institute of Australia).